Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

Question 2

How does sintilimab compare to the standard chemotherapy options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of sintilimab versus the standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer clinical trial (NCT05236972). Contact the study team or your healthcare provider for specific answers.

What this study is about